Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
30.72
+0.52 (1.72%)
At close: Jan 6, 2026, 4:00 PM EST
31.52
+0.80 (2.59%)
After-hours: Jan 6, 2026, 5:43 PM EST
Viridian Therapeutics Stock Forecast
Stock Price Forecast
The 11 analysts that cover Viridian Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $40.45, which forecasts a 31.67% increase in the stock price over the next year. The lowest target is $26 and the highest is $61.
Price Target: $40.45 (+31.67%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Viridian Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 4 | 6 | 5 | 5 |
| Buy | 5 | 5 | 5 | 4 | 6 | 6 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 10 | 11 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Maintains $34 → $42 | Strong Buy | Maintains | $34 → $42 | +36.72% | Dec 23, 2025 |
| Wedbush | Wedbush | Buy Maintains $42 → $47 | Buy | Maintains | $42 → $47 | +52.99% | Dec 10, 2025 |
| William Blair | William Blair | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Dec 3, 2025 |
| Truist Securities | Truist Securities | Strong Buy Initiates $41 | Strong Buy | Initiates | $41 | +33.46% | Nov 24, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $41 → $45 | Buy | Maintains | $41 → $45 | +46.48% | Nov 6, 2025 |
Financial Forecast
Revenue This Year
79.60M
from 302.00K
Increased by 26,257.62%
Revenue Next Year
88.11M
from 79.60M
Increased by 10.69%
EPS This Year
-4.23
from -3.07
EPS Next Year
-3.78
from -4.23
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 132.0M | 217.7M | ||||
| Avg | 79.6M | 88.1M | ||||
| Low | 289,100 | 14.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 43,608.6% | 173.5% | ||||
| Avg | 26,257.6% | 10.7% | ||||
| Low | -4.3% | -81.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -3.52 | -2.45 | ||||
| Avg | -4.23 | -3.78 | ||||
| Low | -4.66 | -4.64 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.